Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Prognostic and therapeutic potential of imbalance between PD‐1+CD8 and ICOS+Treg cells in advanced HBV‐HCC
by
Zhu, Bingbing
, Zhang, Qun
, Yang, Zhiyun
, Zhang, Yi
, Yan, Fengna
, Shi, Ke
, Wang, Xianbo
, Zeng, Xuanwei
in
Antigens
/ Apoptosis
/ CD8 antigen
/ Cell proliferation
/ Clinical outcomes
/ Flow cytometry
/ Hepatitis B
/ hepatitis B virus‐associated hepatocellular carcinoma
/ Hepatocellular carcinoma
/ ICOS+Tregs
/ Immune checkpoint inhibitors
/ immune imbalance
/ Immunological memory
/ Immunotherapy
/ Liver cancer
/ Lymphocytes
/ Lymphocytes T
/ Medical prognosis
/ Memory cells
/ PD‐1+CD8 cells
/ Prognosis
/ tumor progression
/ Viral infections
2024
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prognostic and therapeutic potential of imbalance between PD‐1+CD8 and ICOS+Treg cells in advanced HBV‐HCC
by
Zhu, Bingbing
, Zhang, Qun
, Yang, Zhiyun
, Zhang, Yi
, Yan, Fengna
, Shi, Ke
, Wang, Xianbo
, Zeng, Xuanwei
in
Antigens
/ Apoptosis
/ CD8 antigen
/ Cell proliferation
/ Clinical outcomes
/ Flow cytometry
/ Hepatitis B
/ hepatitis B virus‐associated hepatocellular carcinoma
/ Hepatocellular carcinoma
/ ICOS+Tregs
/ Immune checkpoint inhibitors
/ immune imbalance
/ Immunological memory
/ Immunotherapy
/ Liver cancer
/ Lymphocytes
/ Lymphocytes T
/ Medical prognosis
/ Memory cells
/ PD‐1+CD8 cells
/ Prognosis
/ tumor progression
/ Viral infections
2024
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Prognostic and therapeutic potential of imbalance between PD‐1+CD8 and ICOS+Treg cells in advanced HBV‐HCC
by
Zhu, Bingbing
, Zhang, Qun
, Yang, Zhiyun
, Zhang, Yi
, Yan, Fengna
, Shi, Ke
, Wang, Xianbo
, Zeng, Xuanwei
in
Antigens
/ Apoptosis
/ CD8 antigen
/ Cell proliferation
/ Clinical outcomes
/ Flow cytometry
/ Hepatitis B
/ hepatitis B virus‐associated hepatocellular carcinoma
/ Hepatocellular carcinoma
/ ICOS+Tregs
/ Immune checkpoint inhibitors
/ immune imbalance
/ Immunological memory
/ Immunotherapy
/ Liver cancer
/ Lymphocytes
/ Lymphocytes T
/ Medical prognosis
/ Memory cells
/ PD‐1+CD8 cells
/ Prognosis
/ tumor progression
/ Viral infections
2024
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Prognostic and therapeutic potential of imbalance between PD‐1+CD8 and ICOS+Treg cells in advanced HBV‐HCC
Journal Article
Prognostic and therapeutic potential of imbalance between PD‐1+CD8 and ICOS+Treg cells in advanced HBV‐HCC
2024
Request Book From Autostore
and Choose the Collection Method
Overview
Over 50% of patients with hepatitis B virus‐associated hepatocellular carcinoma (HBV‐HCC) are diagnosed at an advanced stage, which is characterized by immune imbalance between CD8+ T cells and regulatory T (Treg) cells that accelerates disease progression. However, there is no imbalance indicator to predict clinical outcomes. Here, we show that the proportion of CD8+ T cells decreases and Treg cells increases in advanced HBV‐HCC patients. During this stage, CD8+ T cells and Treg cells expressed the coinhibitory molecule PD‐1 and the costimulatory molecule ICOS, respectively. Additionally, the ratio between PD‐1+CD8 and ICOS+Tregs showed significant changes. Patients were further divided into high‐ and low‐ratio groups: PD‐1+CD8 and ICOS+Tregs high‐ (PD‐1/ICOShi) and low‐ratio (PD‐1/ICOSlo) groups according to ratio median. Compared with PD‐1/ICOSlo patients, the PD‐1/ICOShi group had better clinical prognosis and weaker CD8+ T cells exhaustion, and the T cell‐killing and proliferation functions were more conservative. Surprisingly, the small sample analysis found that PD‐1/ICOShi patients exhibited a higher proportion of tissue‐resident memory T (TRM) cells and had more stable killing capacity and lower apoptosis capacity than PD‐1/ICOSlo advanced HBV‐HCC patients treated with immune checkpoint inhibitors (ICIs). In conclusion, the ratio between PD‐1+CD8 and ICOS+Tregs was associated with extreme immune imbalance and poor prognosis in advanced HBV‐HCC. These findings provide significant clinical implications for the prognosis of advanced HBV‐HCC and may serve as a theoretical basis for identifying new targets in immunotherapy. Imbalance between CD8+ T cells and regulatory T (Treg) cells accelerates disease progression, but there is no imbalance indicator to predict clinical outcomes. The ratio between PD‐1+CD8 and ICOS+Tregs was associated with extreme immune imbalance and poor prognosis in advanced hepatitis B virus‐associated hepatocellular carcinoma (HBV‐HCC).
Publisher
John Wiley & Sons, Inc
MBRLCatalogueRelatedBooks
Related Items
Related Items
We currently cannot retrieve any items related to this title. Kindly check back at a later time.
This website uses cookies to ensure you get the best experience on our website.